Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
-
Narrado por:
-
De:
Acerca de esta escucha
Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared.
Opler, a managing director at Stifel, spoke to Editor in Chief Simone Fishburn on The BioCentury Show about why he’s optimistic about FDA, what he sees ahead for capital markets, competition in China, and three areas of innovation he’s focused on -- aging, women's health and the brain.
View full story: https://www.biocentury.com/article/656040
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #FDA
00:00 - Introduction
01:30 FDA under Trump 2.0
08:07 State of Capital Markets
13:13 China Competition
17:09 Innovation: Aging, Women’s Health & the Brain